The Swiss firm's assay combines a 29-gene host immune response panel with two tumor-derived proteins to detect early-stage colorectal cancer and large adenomatous polyps.
The company did not specify the number of shares it will offer or the offering price, but said it intends to trade on the Nasdaq Global Market.
The supply agreement was originally established between BG and the now defunct Health Diagnostics Laboratory, which was formerly BG's biggest customer.
Researchers from Protagen, Targos, and elsewhere have identified autoantibody biomarkers specific to patients diagnosed with prostate cancer.
The company said it plans to launch a clinical trial to validate its Immray PanCan-d blood test in both Europe and the US.
While much attention has focused on triple quads, MALDI-TOFs offer advantages in simplicity and throughput that could help them make clinical inroads.
The decision lets Vermillion access Medi-Cal's patient network, which covers more than 12.6 million lives, or roughly a third of California's covered lives.
In a large, prospective study published in Lancet Oncology, the screening assay was projected to reduce the number of prostate biopsies by 32 percent.
The company presented new data at a meeting last week showing that Vectra DA predicted whether patients would do better on one or the other of two possible second-line therapies.
The sensor features a DNA-based steric hindrance method, and can detect the presence of antibodies in whole blood in less than 10 minutes.
The deal provides Sciex with the rights to commercialize immune-MRM technology developed by Amanda Paulovich's laboratory.
OncoPlex operates a CAP-accredited and CLIA-certified laboratory and provides mass spectrometry-based tumor profiling services.
The funding will be used to further expand the company's clinical testing products and services in the US and abroad.
Using a self-similar chain-based device combined with Raman spectroscopy, they were able to detect the BRCA1 missense mutation M1775R at picomolar levels.
The investment bank has a $4 price target on Vermillion's stock and noted the firm's OVA2 test, a change to its relationship with Quest, and new management.
The proteomics-based diagnostics firm will use proceeds from the financing for continued commercial development, prospective clinical trials, and other purposes.
The core will serve as a center for receiving, qualifying, processing, and distributing biospecimens to the Clinical Proteomic Tumor Analysis Consortium.
Health Net's coverage of Biodesix's proteomic test for non-small cell lung cancer follows similar decisions last month by Aetna and Cigna.
The reverse stock split was done in order for BG Medicine to remain listed on Nasdaq, which had warned the firm in September of possible delisting action.
The company repurchased a total of 860,595 shares of its common stock, with the price based on a simple average of closing prices for a trailing 60-day period.
The UK's Nuffield Council on Bioethics says genetically modifying human embryos could be morally permissible, according to the Guardian.
A new Nature Biotechnology paper reports that CRISPR-Cas9 gene editing can lead to large deletions or complex rearrangements that could be pathogenic.
The Wall Street Journal likens a prototype developed by Synthetic Genomics to a "biological fax machine."
In PNAS this week: strategy for reactivating Rett syndrome-linked MECP2, small molecules able to suppress Staphylococcus aureus virulence, and more.